Hepatocellular carcinoma (HCC) is the most common liver cancer and the
leading cause of cancer-related deaths. Advanced HCC has a poor prognosis with
limited treatment option. Chronic liver diseases and cirrhosis are the main risk factors
for the development of HCC. Phosphoinositide 3-kinase PI3K/AKT/mTOR,
intracellular mediators play a very important role in the development and progression
of HCC. This signaling pathway is frequently activated in HCC patients. Therefore,
signaling pathways have become the main source of targets for new treatments in HCC
patients.
In our chapter, we will discuss the role of PI3K/AKT/mTOR signaling pathway in the
pathology of HCC and provide an update on the preclinical and clinical approaches for
the development of various molecular agents targeting this proliferation/survival
pathway, which include various PI3K/Akt/mTOR inhibitors and other agents for the
treatment of HCC.
Keywords: Hepatocellular carcinoma, Inhibitors, Signaling pathways, Sorafenib,
Therapy.
